Molidustat is an investigational drug.
There have been 10 clinical trials for Molidustat.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 22nd 2018.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Renal Insufficiency, and Anemia. The leading clinical trial sponsors are Bayer and [disabled in preview].
There are twelve US patents protecting this investigational drug and two hundred and eighty-three international patents.